Back to top
more

Veracyte (VCYT)

(Real Time Quote from BATS)

$42.99 USD

42.99
242,229

-0.20 (-0.46%)

Updated Sep 1, 2026 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of +59.38% and +5.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IDXX Stock Climbs on Q3 Earnings and Revenue Beat, '25 View Up

by Zacks Equity Research

IDEXX stock jumps after Q3 earnings and revenue beat, fueled by double-digit CAG and LPD growth and raised 2025 guidance.

Zacks Equity Research

Idexx Laboratories (IDXX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of +8.28% and +3.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash

by Zacks Equity Research

Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.

Zacks Equity Research

ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash

by Zacks Equity Research

Align Technology jumps 15% after Q3 earnings and revenues beat estimates, though steep margin declines weigh on results.

Zacks Equity Research

CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash

by Zacks Equity Research

Chemed's Q3 miss sends shares lower as shrinking margins and weaker EPS overshadow steady revenue gains from VITAS and Roto-Rooter.

Sridatri Sarkar headshot

LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down

by Sridatri Sarkar

Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.

Zacks Equity Research

ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.

Zacks Equity Research

ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines

by Zacks Equity Research

Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.

Zacks Equity Research

Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up

by Zacks Equity Research

BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.